Camizestrant — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

4 Recruiting

5 Completed trials

3 Sponsors

19 Countries

Phase III

Phase II

Phase I (FiH)

Phase III: 6 Phase II: 2 Phase I (FiH): 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Hormone receptor positive breast cancer 1 Hormone receptor positive HER2 negative breast cancer 1

Sponsors using this IMP

AstraZeneca AB 8 Medica Scientia Innovation Research S.L. 1 Unicancer 1

All trials

10 total

TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending

2025-524213-84-00 Phase III 1 country Unicancer
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C… Recruiting

2024-520027-88-00 Phase II 2 countries Medica Scientia Innovation Research S.L.
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Phase III 10 countries AstraZeneca AB
A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting

2023-507305-33-00 Phase I (FiH) 1 country Astrazeneca AB
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 Phase III 16 countries AstraZeneca AB
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 Phase III 14 countries Astrazeneca AB
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Phase III 12 countries AstraZeneca AB
Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended

2022-502856-29-00 Phase I (FiH) 5 countries AstraZeneca AB
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Phase III 13 countries AstraZeneca AB
A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g… Ended

2023-504974-40-00 Phase II 7 countries AstraZeneca AB

Showing 1–10 of 10 trials

← All drugs A–Z